Candid Health Lands $120M to Push Autonomous Billing Deeper

Candid Health Lands $120M Series D to Scale Autonomous RCM Platform

Candid Health closed a $120 million Series D funding round to expand its autonomous revenue cycle platform, Pulse 2.0, which the company says automates end-to-end billing workflows from claim submission through denial management. The round signals sustained investor confidence in AI-driven RCM automation, even as healthcare providers remain cautious about vendor consolidation and workflow disruption.

The Deal

Candid Health raised $120 million in Series D funding. The company did not disclose valuation or close date publicly, but the round underscores continued venture appetite for RCM automation platforms that promise to reduce days in AR and denial rates at scale. Pulse 2.0, the centerpiece of the raise, reportedly targets mid-market and enterprise health systems struggling with high-touch billing operations and staff retention.

What It Means for RCM

• Automation scope matters: Platforms claiming "end-to-end" autonomous workflows—from claim scrubbing to appeals—will face higher scrutiny from billing teams on accuracy rates, payer rejection thresholds, and edge-case handling. Candid's funding gives it runway to prove Pulse 2.0 works at volume.
• Vendor consolidation pressure: Large Series D rounds accelerate M&A in the RCM space. Hospitals evaluating best-of-breed vs. integrated platforms should expect more acquisition activity and platform wind-downs in the next 18-24 months.
• Denial management competition heats up: As denial rates stay elevated, platforms that can demonstrate measurable reductions in claim rejections and faster time-to-resolution will command premium contract terms. Candid's focus on denial automation puts it head-to-head with pure-play denial management vendors.

Market Context

Healthcare RCM software remains one of the most heavily funded segments in healthtech, driven by provider pain around staffing, compliance complexity, and payor prior authorization delays. Series D and later-stage rounds in RCM have picked up pace over the past 18 months, with investors betting that AI-powered claim intelligence and workflow automation can measurably compress billing cycles and improve cash flow. However, adoption risk remains high—many health systems have burned through RCM vendors that overpromised on automation and underdelivered on integration with legacy EHR systems. Candid's track record and customer base will be the real test of whether Pulse 2.0 scales as promised.

Published by RevCycleAI Research · July 29, 2026